Today Werfen announced the opening of a new building, expanding its capabilities for innovation in Specialized Diagnostics, at its Hemostasis and Acute Care Diagnostics Technology Center in Bedford, MA, USA. Werfen’s Chairman, Marc Rubiralta, along with other senior leaders from Werfen, held a ribbon-cutting ceremony at the Bedford campus. The new building adds 105,000 additional square feet, and represents an investment of more than $50 million. The Hemostasis and Acute Care Diagnostics Technology Center is the largest within Werfen’s global network.

In 2009, Werfen established its Technology Center in Bedford with 600 employees. As business success accelerated, the Company continued to invest in infrastructure to ensure state-of-the-art operations and grow its employee population. Today, the employee base at this location has increased to more than 1,200 strong, and with the new building, has the potential capacity of up to 2,000 employees, allowing growth of its innovation program for several years to come.

“Our expanded Technology Center represents the commitment of our shareholders and the Company to the Commonwealth of Massachusetts, as the optimal hub for healthcare innovation, with some of the finest academic and research institutions and scientists in the world,” said Giovanni Russi, Chief Operating Officer, Hemostasis and Acute Care Diagnostics, at Werfen. “Bedford, with close proximity to Boston, is an ideal location for our continued long-term investments in the research, development, and manufacturing of Specialized Diagnostics.”

Werfen’s success is based on the positive impact its Specialized Diagnostic solutions have on clinicians and the patients they care for, all over the world. The Company’s areas of clinical focus include: Hemostasis, Acute Care, Transfusion, Autoimmunity and Transplant. Today, Werfen is comprised of more than 7,000 employees globally, with approximately 55% based in the US, and 15% in Bedford.